Efbemalenograstim alfa, an Fc fusion protein, long-acting granulocyte-colony stimulating factor for reducing the risk of febrile neutropenia following chemotherapy: results of a phase III trial

By sjmartinez • December 17, 2023

Glaspy J, Bondarenko I, Burdaeva O, Chen J, Rutty D, Li R, Wang S, Hou Q, Li S. Efbemalenograstim alfa, an Fc fusion protein, long-acting granulocyte-colony stimulating factor for reducing the risk of febrile neutropenia following chemotherapy: results of a phase III trial. Support Care Cancer. 2023 Dec 16;32(1):34. doi: 10.1007/s00520-023-08176-6. PMID: 38103088; PMCID: PMC10725375.

Tags: breast cancer, Docetaxel /doxorubicin therapy, Efbemalenograstim alfa, Febrile neutropenia, Fusion protein, Granulocyte-colony stimulating factor, Hematology/Oncology, Publications

Tumor-Specific EphA2 Receptor Tyrosine Kinase Inhibits Anti-Tumor Immunity by Recruiting Suppressive Myeloid Populations in Murine Models of Non-Small Cell Lung Cancer

Shiuan E, Wang S, Brantley-Sieders DM. Tumor-Specific EphA2 Receptor Tyrosine Kinase Inhibits Anti-Tumor Immunity by Recruiting Suppressive Myeloid Populations in Murine Models of Non-Small Cell[...]

Prediction of Early Neoadjuvant Chemotherapy Response of Breast Cancer through Deep Learning-based Pharmacokinetic Quantification of DCE MRI

Wu C, Wang L, Wang N, Shiao S, Dou T, Hsu YC, Christodoulou AG, Xie Y, Li D. Prediction of Early Neoadjuvant Chemotherapy Response of[...]

Addressing the Unmet Need for Treatment in Advanced Hepatocellular Carcinoma With Child-Pugh C Cirrhosis: A Case of a Woman With Hepatocellular Carcinoma and Advanced Liver Disease

Chamberlain E, Cleveland JM. Addressing the Unmet Need for Treatment in Advanced Hepatocellular Carcinoma With Child-Pugh C Cirrhosis: A Case of a Woman With Hepatocellular[...]